You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

Investigational Drug Information for Cannabidivarin


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Cannabidivarin?

Cannabidivarin is an investigational drug.

There have been 8 clinical trials for Cannabidivarin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.

The most common disease conditions in clinical trials are Disease, Child Development Disorders, Pervasive, and Autistic Disorder. The leading clinical trial sponsors are GW Research Ltd, GW Pharmaceuticals Ltd., and Montefiore Medical Center.

There are ninety-seven US patents protecting this investigational drug and four hundred and eighty-three international patents.

Recent Clinical Trials for Cannabidivarin
TitleSponsorPhase
Treatment With Cannabis Oil Containing CBD Only or 20:1 CBD:THC vs. Placebo of Persons With ADHDElkana KohnPhase 2
Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case SeriesGregory L Smith, MD, MPHEarly Phase 1
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)Foundation for Prader-Willi ResearchPhase 2

See all Cannabidivarin clinical trials

Clinical Trial Summary for Cannabidivarin

Top disease conditions for Cannabidivarin
Top clinical trial sponsors for Cannabidivarin

See all Cannabidivarin clinical trials

US Patents for Cannabidivarin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cannabidivarin ⤷  Sign Up Crystalline cannabidivarin S&B Pharma, Inc. (Azusa, CA) ⤷  Sign Up
Cannabidivarin ⤷  Sign Up Process to extract and purify .DELTA..sup.9-tetrahydrocannabinol Axim Biotechnologies, Inc. (New York, NY) ⤷  Sign Up
Cannabidivarin ⤷  Sign Up Use of cannabinoids in the treatment of epilepsy GW Pharma Limited (Vision Park, Histon, Cambridge, GB) ⤷  Sign Up
Cannabidivarin ⤷  Sign Up Food and beverage compositions infused with lipophilic active agents and methods of use thereof ⤷  Sign Up
Cannabidivarin ⤷  Sign Up Use of cannabinoids in the treatment of epilepsy GW Pharma Limited (Vision Park, Histon, Cambridge, unknown) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cannabidivarin

Drugname Country Document Number Estimated Expiration Related US Patent
Cannabidivarin European Patent Office EP3291806 2035-05-07 ⤷  Sign Up
Cannabidivarin Morocco MA42057 2035-05-07 ⤷  Sign Up
Cannabidivarin World Intellectual Property Organization (WIPO) WO2016179247 2035-05-07 ⤷  Sign Up
Cannabidivarin Australia AU2015332212 2034-10-14 ⤷  Sign Up
Cannabidivarin Australia AU2021204353 2034-10-14 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.